Selegiline (L-Deprenyl) and L-Dopa Treatment of Parkinson's Disease: A Double-Blind Trial.

Petal and Stigma of Crocus sativus L. in the Treatment of Depression: A Pilot Double - blind Randomized Trial

Stigma of Crocus sativus L. (Iridaceae), commonly known as saffron, is the world’s most expensive spice and apart from its traditional value as food additive recent studies indicate its potential as antidepressant. Because saffron is expensive, using it daily to address depression may not be practical. Moreover, recent study indicated antidepressant effect of petal of Crocus sativus. As petal o...

Cynara scolymus L. in Treatment of Hypercholesterolemic Type 2 Diabetic Patients: a Randomized Double-Blind Placebo-Controlled Clinical Trial

Background: Type 2 diabetes mellitus with hyperlipidemia is a common disease. Conventional anti-hyperglycemic and anti-hyperlipidemic drugs have limited efficacies and important side effects, so that alternative agents are needed. Previous studies suggest that fiber-free artichoke (Cynara scolymus L.) leaf extract may have anti-hyperglycemic and anti-hypercholesterolemic effects in hypercholest...

Antidepressant Effect of Asperugo procumbens L. in Comparison with Fluoxetine: a Randomized Double Blind Clinical Trial

Background and objectives: Aseprugo procumbens is used as antianxety and depression in Iranian traditional medicine; however no clinical trial has been performed about these properties. The aim of this study was to evaluate the antidepressant efficacy and safety of hydroalcoholic extract of A. procumbens. Methods: In this double blind study, 3...

Bensarazid with L-dopa in the treatment of parkinson's disease.

A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease

BACKGROUND In Japan, selegiline has been approved for combination therapy with levodopa for Parkinson disease (PD). We conducted a trial of selegiline monotherapy for early PD. METHODS In this 12-week controlled phase III trial, a total of 292 subjects were randomized to receive placebo (n = 146) (full analysis set 140) or selegiline (n = 146) (full analysis set 139). The primary outcome meas...